Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F E Cotter

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Seminars in Hematology|October 26, 1999
Antisense therapy of hematologic malignanciesF E Cotter
Cancer Surveys|January 1, 1993
Molecular pathology of lymphomasF E Cotter
Hematology (Amsterdam, Netherlands)|July 14, 2016
Antisense Oligonucleotides: Considerations for Lymphoma TherapyF E Cotter
Hematological Oncology|February 1, 1997
Antisense therapy for lymphomasF E Cotter
Clinical and Laboratory Haematology|February 10, 1999
Assessment of cell deathF E Cotter
Bailliere'S Clinical Haematology|January 20, 2000
Childhood myeloproliferative disordersF E Cotter
Haematologica|July 25, 2000
Antisense oligonucleotides for haematological malignanciesF E Cotter
British Journal of Haematology|August 1, 1990
The role of the bcl-2 gene in lymphomaF E Cotter
The British Journal of Clinical Practice|May 1, 1988
Therapeutic milestones. Novantrone (mitozantrone)F E Cotter
Cancer Surveys|January 1, 1997
Antisense therapy for B cell lymphomasF E Cotter
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Seminars in Hematology|October 26, 1999
Antisense therapy of hematologic malignanciesF E Cotter
Cancer Surveys|January 1, 1993
Molecular pathology of lymphomasF E Cotter
Hematology (Amsterdam, Netherlands)|July 14, 2016
Antisense Oligonucleotides: Considerations for Lymphoma TherapyF E Cotter
Hematological Oncology|February 1, 1997
Antisense therapy for lymphomasF E Cotter
Clinical and Laboratory Haematology|February 10, 1999
Assessment of cell deathF E Cotter
Bailliere'S Clinical Haematology|January 20, 2000
Childhood myeloproliferative disordersF E Cotter
Haematologica|July 25, 2000
Antisense oligonucleotides for haematological malignanciesF E Cotter
British Journal of Haematology|August 1, 1990
The role of the bcl-2 gene in lymphomaF E Cotter
The British Journal of Clinical Practice|May 1, 1988
Therapeutic milestones. Novantrone (mitozantrone)F E Cotter
Cancer Surveys|January 1, 1997
Antisense therapy for B cell lymphomasF E Cotter
Pageof 8